To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Gene replacement therapy … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy

Journal article
Authors N. Schiza
E. Georgiou
A. Kagiava
J. J. Medard
J. Richter
C. Tryfonos
I. Sargiannidou
A. J. Heslegrave
A. M. Rossor
Henrik Zetterberg
M. M. Reilly
C. Christodoulou
R. Chrast
K. A. Kleopa
Published in Brain
Volume 142
Pages 1227-1241
ISSN 0006-8950
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 1227-1241
Language en
Links dx.doi.org/10.1093/brain/awz064
Keywords Charcot-Marie-Tooth 4C disease, peripheral neuropathy, gene therapy, Schwann cells, biomarkers, plasma-membrane, na+ channels, spinal-cord, disease, sh3tc2, protein, myelination, delivery, mutations, gliomedin, Neurosciences & Neurology
Subject categories Neurochemistry

Abstract

Charcot-Marie-Tooth disease type 4C is the most common recessively inherited demyelinating neuropathy that results from loss of function mutations in the SH3TC2 gene. Sh3tc2(-/-) mice represent a well characterized disease model developing early onset progressive peripheral neuropathy with hypo- and demyelination, slowing of nerve conduction velocities and disturbed nodal architecture. The aim of this project was to develop a gene replacement therapy for treating Charcot-Marie-Tooth disease type 4C to rescue the phenotype of the Sh3tc2(-/-) mouse model. We generated a lentiviral vector LV-Mpz.SH3TC2.myc to drive expression of the human SH3TC2 cDNA under the control of the Mpz promoter specifically in myelinating Schwann cells. The vector was delivered into 3-week-old Sh3tc2(-/-) mice by lumbar intrathecal injection and gene expression was assessed 4-8 weeks after injection. Immunofluorescence analysis showed presence of myc-tagged human SH3TC2 in sciatic nerves and lumbar roots in the perinuclear cytoplasm of a subset of Schwann cells, in a dotted pattern co-localizing with physiologically interacting protein Rab11. Quantitative PCR analysis confirmed SH3TC2 mRNA expression in different peripheral nervous system tissues. A treatment trial was initiated in 3 weeks old randomized Sh3tc2(-/-) littermate mice which received either the full or mock (LV-Mpz.Egfp) vector. Behavioural analysis 8 weeks after injection showed improved motor performance in rotarod and foot grip tests in treated Sh3tc2(-/-) mice compared to mock vector-treated animals. Moreover, motor nerve conduction velocities were increased in treated Sh3tc2(-/-) mice. On a structural level, morphological analysis revealed significant improvement in g-ratios, myelin thickness, and ratios of demyelinated fibres in lumbar roots and sciatic nerves of treated Sh3tc2(-/-) mice. Finally, treated mice also showed improved nodal molecular architecture and reduction of blood neurofilament light levels, a clinically relevant biomarker for axonal injury/degeneration. This study provides a proof of principle for viral gene replacement therapy targeted to Schwann cells to treat Charcot-Marie-Tooth disease type 4C and potentially other similar demyelinating inherited neuropathies.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?